New efficacy data for ARJUNA Therapeutics Ag5 to be presented at the 2025 AACR Meeting

SANTIAGO DE COMPOSTELA, Spain - April 4, 2025 - PRLog --

 
• New in vitro and in vivo model efficacy and biomarker data from patient derived Glioblastoma Multiforme samples will add to the already strong preclinical data package for ARJUNA Therapeutics Ag5
• The Ag5 programme remains on track to commence human trials in 2027

ARJUNA Therapeutics, a preclinical oncology company is pleased to announce the presentation of new preclinical Glioblastoma Multiforme PDX mouse model efficacy and biomarker data by our collaborators, the De Smet Lab at KU Leuven, Belgium at the American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago April 25-30, 2025.

"We are delighted that Professor De Smet lab's poster has been selected by the AACR's scientific committee to present new data on Ag5 efficacy at this very important scientific meeting. This validates our goal that Ag5 will bring hope to glioblastoma patients and their families" said Dr Ross Breckenridge PhD, FRCP, CEO of ARJUNA Therapeutics.

Session Category: Experimental and Molecular Therapeutics

Session Title: Novel Antitumor Agents 4

Date & Time: April 30, 2025, 9:00 a.m. – 12:00 p.m.

Location: Poster Section 21

Poster Board Number: 22

Title: Ag5: A novel quantum cluster therapy targeting mitochondria and antioxidant systems in glioblastoma.

Published Abstract Number: 6878

Session Type: Minisymposium

Session Title: Diagnostic and Predictive Biomarkers
Session Start Time: 4/29/2025 2:30:00 PM
Session End Time: 4/29/2025 4:30:00 PM
Location: Location to be announced
Role / Presentation Title: Characterization of therapeutic effects in glioblastoma through integrated spatial single-cell multiome profiling of longitudinal samples: Unveiling clinically relevant subtypes of pathological changes

About Ag5

Ag5 is the first of the Therapeutic Molecular Cluster™ (TMC™) platform of novel small molecules synthesised by ARJUNA Therapeutics using  quantum chemistry. The unique mechanism of Ag5 is rapid, tumor-cell-specific deactivation of all mitochondrial antioxidant pathways overcoming antioxidant redundancy and inducing cell death with free passage across the blood brain barrier and minimal off target effects. Clinical trials for Ag5 in GBM and Non-Small-Cell Lung cancer with brain metastasis are planned to start in 2027.

Find out more: www.arjunatherapeutics.com